Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas

The p53 and phosphoinositide‐3‐kinase, catalytic, alpha polypeptide/v‐akt murine thymoma viral oncogene homolog/mechanistic target of rapamycin (PIK3CA/AKT/mTOR) pathways frequently are altered in sarcoma with complex genomics, such as leiomyosarcoma (LMS) or undifferentiated pleomorphic sarcoma (UPS). The scale of genetic abnormalities in these pathways remains unknown in angiosarcoma (AS).

[1]  S. Voss,et al.  Leukemia and lymphoma. , 2011, Radiologic clinics of North America.

[2]  K. Lindblad-Toh,et al.  Refining tumor-associated aneuploidy through ‘genomic recoding’ of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas , 2011, Leukemia & lymphoma.

[3]  Kecheng Zhang,et al.  Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. , 2011, Histology and Histopathology.

[4]  D. Stoppa-Lyonnet,et al.  EMMA, a cost‐ and time‐effective diagnostic method for simultaneous detection of point mutations and large‐scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients , 2011, Human mutation.

[5]  V. de Giorgi,et al.  Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy , 2011, Histopathology.

[6]  C. Antonescu,et al.  Consistent MYC and FLT4 gene amplification in radiation‐induced angiosarcoma but not in other radiation‐associated atypical vascular lesions , 2011, Genes, chromosomes & cancer.

[7]  David M. Thomas,et al.  Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis , 2010, Clinical Cancer Research.

[8]  F. Chibon,et al.  Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. , 2010, The American journal of pathology.

[9]  M. Landthaler,et al.  Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. , 2010, Anticancer research.

[10]  Derek Y. Chiang,et al.  Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.

[11]  C. Harris,et al.  Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.

[12]  J. Hunt,et al.  Allelic loss of 3 different tumor suppressor gene loci in benign and malignant endothelial tumors of the head and neck. , 2009, Archives of pathology & laboratory medicine.

[13]  Narasimhan P. Agaram,et al.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. , 2009, Cancer research.

[14]  L. Qin,et al.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[16]  K. Hunt,et al.  Genetic aberrations in soft tissue leiomyosarcoma. , 2009, Cancer letters.

[17]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[18]  Gerald C. Chu,et al.  P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.

[19]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[20]  Zhou Xiaoyan,et al.  Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[21]  R. Mason,et al.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.

[22]  P. Pandolfi,et al.  PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. , 2008, Genes & development.

[23]  J. Blay,et al.  Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  D. Stoppa-Lyonnet,et al.  High‐throughput simultaneous detection of point mutations and large‐scale rearrangements by CE , 2007, Electrophoresis.

[25]  G. Tate,et al.  Mutation of the PTEN gene in a human hepatic angiosarcoma. , 2007, Cancer genetics and cytogenetics.

[26]  Dihua Yu,et al.  High prevalence of p53 exon 4 mutations in soft tissue sarcoma , 2007, Cancer.

[27]  P. Pandolfi,et al.  The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.

[28]  F. Chibon,et al.  Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity , 2007, European Journal of Human Genetics.

[29]  R. Maki,et al.  Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[31]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[32]  B. Gunawan,et al.  Comparative genomic hybridization in four angiosarcomas of the female breast. , 2005, Gynecologic oncology.

[33]  A. Balmain,et al.  Genetic interactions between Pten and p53 in radiation-induced lymphoma development , 2003, Oncogene.

[34]  M. Solé,et al.  Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial Dysplasia , 2003, Modern Pathology.

[35]  N. Wong,et al.  Sinonasal angiosarcoma with marrow involvement at presentation mimicking malignant lymphoma: cytogenetic analysis using multiple techniques. , 2001, Cancer genetics and cytogenetics.

[36]  Y. Zu,et al.  Chromosomal Abnormalities and p53 Gene Mutation in a Cardiac Angiosarcoma , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[37]  D. Wiederschain,et al.  Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. , 2000, The American journal of pathology.

[38]  A. Zeiher,et al.  Akt takes center stage in angiogenesis signaling. , 2000, Circulation research.

[39]  P. Vogt,et al.  The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Sendelhofert,et al.  MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. , 1998, The American journal of pathology.

[41]  L. Cerilli,et al.  Primary renal angiosarcoma: a case report with immunohistochemical, ultrastructural, and cytogenetic features and review of the literature. , 1998, Archives of pathology & laboratory medicine.

[42]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[43]  T. Ochi,et al.  Mutations of p53 tumor‐suppressor gene in angiosarcoma , 1997, International journal of cancer.

[44]  C. Cordon-Cardo,et al.  Alterations of tumor suppressor genes in bladder cancer. , 1997, Seminars in diagnostic pathology.

[45]  K. Ishak,et al.  p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. , 1995, Carcinogenesis.

[46]  A. Llombart‐Bosch,et al.  Cytogenetic study of angiosarcoma of the breast , 1994, Genes, chromosomes & cancer.

[47]  E. van den Berg,et al.  Comparison of cytogenetic abnormalities and deoxyribonucleic acid ploidy of benign, borderline malignant, and different grades of malignant soft tissue tumors. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[48]  F. Mitelman,et al.  Trisomy 5 and loss of the Y chromosome as the sole cytogenetic anomalies in a cavernous hemangioma/angiosarcoma , 1990, Genes, chromosomes & cancer.

[49]  E. Freireich.  Leukemia and lymphoma. , 1971, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[50]  A. Marx,et al.  MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. , 2010, The American journal of pathology.

[51]  L. Kindblom,et al.  Morphological and cytogenetic studies of angiosarcoma in Stewart-Treves syndrome , 2005, Virchows Archiv A.

[52]  A. Tannapfel,et al.  Mutation analysis of K‐ras‐2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride , 2002, Environmental and molecular mutagenesis.

[53]  Y. Amo,et al.  Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation. , 2002, Acta dermato-venereologica.

[54]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[55]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[56]  C. Harris,et al.  p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. , 1994, Carcinogenesis.